South & Central America Gastrointestinal Drugs Market to Grow at a CAGR of 4.0% to reach US$ 5,632.72 Million from 2020 to 2027

South & Central America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country

  • Report Code : TIPRE00016303
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 133
Buy Now

The South and Central America gastrointestinal drugs market is expected to reach US$ 5,632.72 million by 2027 from US$ 4,160.28 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027.



Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the South & Central America Gastrointestinal Drugs market

Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.

Gastrointestinal diseases are the conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhoea. GI diseases account for substantial health care utilization and spending. Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Several studies have highlighted the accelerated growth of gastrointestinal diseases in South America’s populations during the past two decades. Both incidence and prevalence rates have shown a notable rise, with scientists pointing out that GI diseases are increasingly the cause of morbidity and mortality in American countries. For instance, the most frequently reported diseases in Brazil are gastritis, followed by GERD, hemorrhoids, irritable-bowel syndrome.

Gastrointestinal (GI) diseases, in particular, are becoming common and have been linked to changing environmental factors brought on by improved sanitation, industrialization, changes in diet, and the increased use of antibiotics. Due to these factors, medical device companies in the GI space have been expanding their business operations in South America. The incidence and prevalence of many GI disorders are highest amongst the very young and the elderly. As the population ages, the disease burden is expected to grow. The incidence and prevalence of IBD have increased in the last few decades. Moreover, in the last few years, the cases of IBD have increased. IBD is a chronic inflammation of the digestive tract and is of two types: Ulcerative colitis and Crohn's disease. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.

South and Central America is hit by the COVID-19 pandemic and thus has profound humanitarian, economic, and political consequences. They have responded to the situation by closing borders, ordering quarantines, and imposing a host of restrictions to keep people confined at home. For instance, Brazilian Health Regulatory Agency (ANVISA) has approved RedHill Biopharma Ltd. to conduct clinical trials for its drug for COVID 19. RedHill Biopharma Ltd.is a specialty biopharmaceutical company focusing on gastrointestinal diseases. RedHill is expected to promote the gastrointestinal drugs, Movantik for opioid-induced constipation in adults. Thus, the gastrointestinal drug market is expected to grow in the forecasted period.

Rest of South and Central America Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)

Rest of South and Central America Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

SOUTH AND CENTRAL AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION

By Drug Class

  • Acid Neutralizers
  • Antidiarrheal and Laxatives
  • Anti-Inflammatory Drugs
  • Antiemetic and Antinauseants
  • Biologics
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Application

  • Inflammatory Ulcerative Colitis
  • Crohn's Disease
  • Irritable Bowel Syndrome
  • Gastroenteritis
  • Celiac Disease
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Country

  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

  • Celltrion Healthcare Co.,Ltd
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug Class, Route of Administration, Application, and Distribution Channel, and Country

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Brazil, Argentina

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 South and Central America Gastrointestinal Drugs Market – By Drug Class

1.3.2 South and Central America Gastrointestinal Drugs Market – By Route of Administration

1.3.3 South and Central America Gastrointestinal Drugs Market – By Application

1.3.4 South and Central America Gastrointestinal drugs Market – By Distribution Channel

1.3.5 South and Central America Gastrointestinal drugs Market – By Country

2. South and Central America Gastrointestinal Drugs Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. South and Central America Gastrointestinal Drugs Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Gastrointestinal Drugs Market - South and Central America PEST Analysis

4.3 Expert Opinion

5. South and Central America Gastrointestinal Drugs Market - Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases

5.1.2 Increase in Development of Biologics

5.2 Market Restraints

5.2.1 Side Effects Associated with The Drugs

5.3 Market Opportunities

5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates

5.4 Future Trends

5.4.1 Emergence of Biosimilars

5.5 Impact Analysis

6. Gastrointestinal Drugs Market – South and Central America Analysis

6.1 South and Central America Gastrointestinal Drugs Market Revenue Forecasts and Analysis

7. South and Central America Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class

7.1 Overview

7.2 South and Central America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

7.2.1 South and Central America Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

7.3 Acid Neutralizers

7.3.1 Overview

7.3.2 South and Central America Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)

7.4 Antidiarrheal and Laxatives

7.4.1 Overview

7.4.2 South and Central America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

7.5 Anti-Inflammatory Drugs

7.5.1 Overview

7.5.2 South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

7.6 Antiemetic and Antinauseants

7.6.1 Overview

7.6.2 South and Central America Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)

7.7 Biologics

7.7.1 Overview

7.7.2 South and Central America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

7.8 Others

7.8.1 Overview

7.8.2 South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. South and Central America Gastrointestinal Drugs Market Analysis – By Route of Administration

8.1 Overview

8.2 South and Central America Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)

8.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

8.3 Oral

8.3.1 Overview

8.3.2 South and Central America Oral Market Revenue and Forecasts to 2027 (US$ Mn)

8.4 Parenteral

8.4.1 Overview

8.4.2 South and Central America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

9. South and Central America Gastrointestinal Drugs Market Analysis – By Application

9.1 Overview

9.2 South and Central America Gastrointestinal Drugs Market, By Application 2019-2027 (%)

9.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)

9.3 Inflammatory Ulcerative Colitis

9.3.1 Overview

9.3.2 South and Central America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

9.4 Crohn's Disease

9.4.1 Overview

9.4.2 South and Central America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.5 Irritable Bowel Syndrome

9.5.1 Overview

9.5.2 South and Central America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

9.6 Gastroenteritis

9.6.1 Overview

9.6.2 South and Central America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

9.7 Celiac Disease

9.7.1 Overview

9.7.2 South and Central America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

9.8 Others

9.8.1 Overview

9.8.2 South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)

10. South and Central America Gastrointestinal Drugs Market Analysis – By Distribution Channel

10.1 Overview

10.2 South and Central America Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)

10.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

10.3 Hospital Pharmacies

10.3.1 Overview

10.3.2 South and Central America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.4 Retail Pharmacies

10.4.1 Overview

10.4.2 South and Central America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

10.5 Online Pharmacies

10.5.1 Overview

10.5.2 South and Central America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis

11.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027

11.1.1 Overview

11.1.2 South and Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)

11.1.3 South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

11.1.4 South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.1.5 South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.1.6 South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

11.1.7 South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)

11.1.8 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2 Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

11.1.8.3 Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.1.8.4 Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.1.8.5 Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

11.1.9 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2 Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

11.1.9.3 Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.1.9.4 Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.1.9.5 Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

11.1.10 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2 Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

11.1.10.3 Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.1.10.4 Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.1.10.5 Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

12. Impact of COVID-19 Pandemic on South and Central America Gastrointestinal Drugs Market

12.1 South and Central America: Impact Assessment of COVID-19 Pandemic

13. Company Profiles

13.1 Takeda Pharmaceutical Company Limited

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Celltrion Healthcare Co.,Ltd.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 AstraZeneca

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Johnson and Johnson Services, Inc.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

14. Appendix

14.1 Glossary of Terms

LIST OF TABLES

Table 1. South and Central America Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)

Table 2. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

Table 3. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)

Table 4. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

Table 5. South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)

Table 6. South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 7. South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 8. South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 9. Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

Table 10. Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 11. Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 12. Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 13. Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

Table 14. Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 15. Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 16. Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 17. Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)

Table 18. Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 19. Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 20. Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)

Table 21. Glossary of Terms, Gastrointestinal Drugs Market

LIST OF FIGURES

Figure 1. Gastrointestinal Drugs Market Segmentation

Figure 2. South and Central America Gastrointestinal Drugs Market Overview

Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market

Figure 4. Brazil is Expected to Show Remarkable Growth During the Forecast Period

Figure 5. South and Central America Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)

Figure 6. Gastrointestinal Drugs Market - South and Central America PEST Analysis

Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint

Figure 8. South and Central America Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027

Figure 9. South and Central America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)

Figure 10. South and Central America Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11. South and Central America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12. South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13. South and Central America Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14. South and Central America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 15. South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16. South and Central America Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)

Figure 17. South and Central America Oral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 18. South and Central America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19. South and Central America Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)

Figure 20. South and Central America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21. South and Central America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22. South and Central America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23. South and Central America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 24. South and Central America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25. South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 26. South and Central America Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)

Figure 27. South and Central America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 28. South and Central America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 29. South and Central America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 30. South and Central America: Gastrointestinal Drugs Market , by Key Country – Revenue (2019) (USD Million)

Figure 31. South and Central America: Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (USD Million)

Figure 32. South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)

Figure 33. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 34. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 35. Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)

Figure 36. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in Rest of the World

  1. Celltrion Healthcare Co.,Ltd
  2. GlaxoSmithKline plc
  3. Johnson and Johnson Services, Inc.
  4. AstraZeneca
  5. Takeda Pharmaceutical Company Limited

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to South & Central America Gastrointestinal Drugs Market